The 11th Annual Event is Coming to San Diego on September 27-28, 2017
Further details about this event will be posted in the coming days

REQUEST A BROCHURE SPEAKING OPPORTUNITIES

Press Releases

July 12, 2016

Nektar Therapeutics Presents Abuse Potential Assessment of Novel Opioid Analgesic NKTR-181 at Arrowhead’s Upcoming 10th Annual Pain Summit

In the past several years, the FDA has been providing an incentive to develop abuse-deterrent products by offering differentiated labeling claims for products that meet the current required standards. Abuse potential, or the likelihood that a drug will be used for its positive psychoactive effects in nonmedical methods, was of crucial concern for Nektar Therapeutics when developing NKTR-181, a novel opioid analgesic. 

June 30, 2016

Precision Treatments for Pain Discovered by Research Team at Yale University to be Shared at 10th Annual Pain Therapeutics Summit
 
An estimated 100 million people in America are in need of better, more personalized treatments for pain, and a team at Yale University has proven how it should be done. Their research has shown that by using a pharmacogenomics approach which analyzes the genomes of patients, it is possible to predict and therefore reduce the likelihood of adverse drug effects. 

 

June 21, 2016

Vivozon to Present Practical Methodology in Identifying Antionociceptive Multi-Target Drugs at Upcoming 10th Annual Pain Therapeutics Summit

As the steady decline of newly developed single-targeted drugs is becoming a challenge in the field, researchers are preferring to use a practical methodology in identifying antionociceptive multi-target drugs. The design of this approach allows for drugs to reflect multifactorial diseases caused by intricate networks of various mechanisms.

August 13, 2012

Advances in Chronic Migraine Treatment

Chronic migraine (CM) and episodic migraine (EM) are part of the spectrum of migraine disorders, but they are distinct clinical entities. Episodic migraine (EM) is characterized by those with migraine who have 0 to 14 headache days per month, while chronic migraine (CM) is characterized by 15 or more headache days per month.
 

About Us

Arrowhead Publishers' conferences offer more than simply presentations; we offer an experience that encompasses learning, networking and professional growth. We focus on bringing life sciences industry professionals together to help move research forward. 
READ MORE

Contact Us

For general information about the conference, please contact us at:
 This email address is being protected from spambots. You need JavaScript enabled to view it.
 +866.945.0263
 +866.945.0263
 5780 Lincoln Drive, Suite 205, Edina, Minnesota 55436 USA